IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
IPO Year: 2021
Exchange: NASDAQ
Website: iobiotech.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/30/2021 | $21.00 | Overweight | Morgan Stanley |
11/30/2021 | Outperform | Cowen & Co. | |
11/30/2021 | $20.00 | Buy | Jefferies |
144 - IO Biotech, Inc. (0001865494) (Subject)
8-K - IO Biotech, Inc. (0001865494) (Filer)
10-Q - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
144 - IO Biotech, Inc. (0001865494) (Subject)
8-K - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
10-Q - IO Biotech, Inc. (0001865494) (Filer)
144 - IO Biotech, Inc. (0001865494) (Subject)
8-K - IO Biotech, Inc. (0001865494) (Filer)
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) taking place taking place in Houston, Texas on November 8-10, 2024. The first abstract accepted for poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in the Company's Phase 2 basket trial of
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed -- -- Data Presented at the European Society for Medical Oncology (ESMO) Congress -- NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, announced promising data from the Phase 2 basket trial of IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025 NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an Independent Data Monitoring Committee (IDMC) recommended continuation of the company's pivotal Phase 3 trial (IOB-013/KN-D1
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences: Event: Morgan Stanley 22nd Annual Global Healthcare ConferenceLocation: New York, New YorkFireside Chat Date & Time: Wednesday, September 4, 2024 at 5:35 pm ETPresenter: Mai-Britt Zocca, PhD, CEOWebcast Link: Here Event: H.C. Wainwright 26th Annual Global Investment ConferenceLocation: New York, New YorkPr
Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN); data from SCCHN cohort has been accepted for poster presentation at the Eu
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-0
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company's CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York, NY. Presentation DetailsDate and Time: Wednesday, June 5, 2024, 7:30-7:55 AM ESTPresenter: Mai-Britt Zocca, Ph.D., President & CEOWebcast Link: https://wsw.com/webcast/jeff302/iobt/1842656
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endpoint of progression free survival (PFS) is now projected to occur in first half of 2025Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 and in first cohort of Phase 2 neoadjuvant/adjuvant basket trial IOB-032/PN-E40, which has been expanded to include a randomized melanoma cohortPresented poster at the American Association for Cancer Research (AACR) Annual Meeting 2024; non-clinical data p
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progress poster from the actively recruiting IOB-032/PN-E40 Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) given in t
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
Morgan Stanley initiated coverage of IO Biotech with a rating of Overweight and set a new price target of $21.00
Cowen & Co. initiated coverage of IO Biotech with a rating of Outperform
Jefferies initiated coverage of IO Biotech with a rating of Buy and set a new price target of $20.00
Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec
Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company's global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma Oral presentation and two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 37thAnnual Meeting this week will provide an overview of the Phase 1/2 study (MM1636) with IO102-IO103 in combination with nivolumab for metastatic melanoma and discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 (ARG1) and Transforming Growth Factor Beta 1 (
SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G - IO Biotech, Inc. (0001865494) (Subject)
SC 13G - IO Biotech, Inc. (0001865494) (Subject)
SC 13G - IO Biotech, Inc. (0001865494) (Subject)
HC Wainwright & Co. analyst Emily Bodnar maintains IO Biotech (NASDAQ:IOBT) with a Buy and raises the price target from $8 to $12.
Gainers SCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million. IO Biotech (NASDAQ:IOBT) stock increased by 11.44% to $1.85. The company's market cap stands at $121.8 million. As per the press release, Q4 earnings came out yesterday. Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 8.11% to $1.6. The market value of their outstanding shares is at $5.1 million. NextCure (NASDAQ:NXTC) shares increased by 8.01% to $1.82. The market value of their outstanding shares is at $50.7 million. Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 7.47% to $0.75. The market value of
HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $8 price target.
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 42.03 percent increase over losses of $(0.69) per share from the same period last year.
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. SOPHiA GENETICS SA (NASDAQ:SOPH) On Jan. 8, SOPHiA GENETICS announced a collaboration with Exacti
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) before and after surgery with curative intent. "We continue to see promising data and a favorable safety profile supporting use of our lead investigational therapeutic cancer vaccine candidate, IO102-IO103, combined with P
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results. The company posted a quarterly net loss of $10.1 million, inclusive of $3.2 million in non-cash items, or 12 cents per share for the fourth quarter, versus a year-ago net loss of $14.3 million, inclusive of $6.0 million in non-cash items, or 18 cents per share for the year-ago period. Anavex Life Sciences shares fell 10% to $6.35 on Monday. Here are some other stocks moving in today's mid-day session. Gainers RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 125% to $0.7063 after the company announced the FDA has granted five years' mark
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. VolitionRx The Trade: VolitionRx Limited (NYSE:VNRX) Director Guy Archibald Innes acquired a total of 20,000 shares an average price of $0.71. To acquire these shares, it cost around $14,200. What’s Happening: EF Hutton reiterated VolitionRX with a Buy
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 23.21 percent increase over losses of $(0.56) per share from the same period last year.
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committeeProgressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumorsEnded 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025 NEW YORK, March
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board. "We are pleased to welcome Helen, an accomplished healthcare executive with extensive drug development and corporate strategy experience, to our Board of Directors," said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. "I look forward
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an accomplished global biotech leader with over 25 years of experience across the pharmaceutical value chain, from clinical and commercial development through to launch execution, will serve on the Audit Committee and the Nominating and Corporate Governance Committee of the Board. In addition, Priyanka Belawat, PhD, has announced that she is stepping down from the company's board of directors, effective imme
Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr. Ahmad joins IO Biotech from Novartis, where he most recently served as Senior Vice President, US Head of Clinical Development & Medical Affairs, for the Novartis Oncology business unit. A trained internist and clinical oncologist, he brings over two decades of successful strategic clinical development, medical affairs, a
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company's lead cancer vaccine candidate. Dr. Richter will report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and will be a member of the company's executive team. "Nearing the recruitment of 225 patients in our global Phase 3 clinical trial for IO102-IO103 in patients with advanced metastatic melanoma, we now expect to have a clear line of sight on both
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment of Devin Smith as the company's first General Counsel and Chief Compliance Officer. Mr. Smith will oversee all company legal activities and provide strategic guidance and corporate governance. "We are excited to welcome Devin as a member of our executive team," said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech. "With over two decades of legal experience in the industry, his knowledge and insight will be invaluable throughout IO
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, today announced the appointment of Amy Sullivan as the company's new Chief Financial Officer. "We are pleased to welcome Amy to the executive team," said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech. "Her financial prowess and successful track record guiding biotechnology companies through significant organizational growth will be an invaluable addition to IO Biotech. On behalf of the entire leadership team, I look forward to Amy's many contributions as w
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors. Mr. Smith, a veteran biotech executive with over 30 years of experience in executive and financial leadership, will serve on the Audit Committee of the Board. "David is a welcome addition to the IO Biotech Board, bringing substantial experience in guiding multiple biotech companies through all stages of development as well as deep expertise in finance and corporate governance," said Mai-Britt Zocca, Ph.D., C